Immune Design and Gritstone Oncology Announce Clinical Collaboration for Neoantigen Cancer Immunotherapy
SEATTLE and SOUTH SAN FRANCISCO, Calif. and EMERYVILLE Calif,, May 09, 2016 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on oncology, and...
Immune Design to Report First Quarter 2016 Financial Results
May 03, 2016 08:00 ET
|
Immune Design Corp.
SEATTLE and SOUTH SAN FRANCISCO, Calif., May 03, 2016 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on cancer, today announced that it will...
Immune Design Announces Presentations at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting
April 21, 2016 08:00 ET
|
Immune Design Corp.
SEATTLE and SOUTH SAN FRANCISCO, Calif., April 21, 2016 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on oncology, today announced that data from...
Immune Design Presents New Preclinical Data on Advances of Two Separate Intratumoral Approaches at the American Association for Cancer Research (AACR) Annual Meeting 2016
April 20, 2016 09:00 ET
|
Immune Design Corp.
Curative Efficacy and Anti-tumor Immunity Demonstrated with Intratumoral Administration of IL-12 by a ZVexTM VectorSystemic Anti-tumor Immunity Demonstrated with Intratumoral G100 SEATTLE and SOUTH...
Immune Design Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Corporate Update
March 10, 2016 16:01 ET
|
Immune Design Corp.
SEATTLE and SOUTH SAN FRANCISCO, Calif., March 10, 2016 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on oncology, today reported financial...
Immune Design’s GLAAS™ Platform Shown to Modulate the Allergic Immune Response
March 04, 2016 08:00 ET
|
Immune Design Corp.
Establishes Potential for the Treatment of Pollen and Peanut Allergies Data Presented at American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting SEATTLE and SOUTH...
Immune Design to Report Fourth Quarter and Year End 2015 Financial Results
March 03, 2016 08:00 ET
|
Immune Design Corp.
SEATTLE and SOUTH SAN FRANCISCO, March 03, 2016 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on cancer, today announced that it will report fourth...
Immune Design to Present at Cowen and Company 36th Annual Health Care Conference
February 29, 2016 08:00 ET
|
Immune Design Corp.
SEATTLE and SOUTH SAN FRANCISCO, Calif., Feb. 29, 2016 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on oncology, today announced that Carlos Paya,...
Immune Design Announces Positive Topline Data From Three Phase 1 Clinical Trials of Immuno-oncology Product Candidates
February 09, 2016 08:00 ET
|
Immune Design Corp.
SEATTLE and SOUTH SAN FRANCISCO, Calif., Feb. 09, 2016 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on oncology, today reported positive topline...
Immune Design to Present at Leerink Partners 5th Annual Global Healthcare Conference
February 04, 2016 08:00 ET
|
Immune Design Corp.
SEATTLE and SOUTH SAN FRANCISCO, Calif., Feb. 04, 2016 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on oncology, today announced that Carlos...